Researchers at China Pharmaceutical University and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have disclosed short transient receptor potential channel 5 (TRPC5) and/or short transient receptor potential channel 4 (TRPC4) ligands reported to be useful for the treatment of cancer and more.